

### Remarks

The original Sequence Listing in the above-captioned patent application was filed on May 18, 1998, in response to the first Notice to comply with requirements for patent applications containing nucleotide sequence and/or amino acids sequence disclosures. This communication is in response to the second Notice to comply, dated March 2, 2001, wherein The Examiner has asked the Applicants to submit a sequence listing for the amino acid sequences recited in claims 9, 31, 41 and 54.

However, we would like to call the Examiner's attention to the fact that the amino acids presented in the claims are not amino acid sequences as required by 37 CFR 1.821-1.825. They are listings of alternative, specific residues that are defined at a particular position for the designated motif. This is clarified in the Preliminary Amendment, filed June 30, 1999, where the referenced amino acid residues are separated by commas.


Due to a forementioned reason, we do not believe that a Sequence Listing is required for the above-captioned patent application.

In the unlikely event that the transmittal letter is separated from this response and the U.S. Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this sequence listing to our **Deposit Account No. 03-1952**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: May 2, 2001

By:



Kate H. Murashige  
Registration No. (29,959)

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125